Metformin does not affect clinically relevant outcomes in patients with idiopathic pulmonary fibrosis / Paolo Spagnolo, Michael Kreuter, Toby M. Maher, Wim Wuyts, Francesco Bonella, Tamera J. Corte, Stefan Kopf, Derek Weycker, Klaus-Uwe Kirchgaessler, Christopher J. Ryerson

BACKGROUND: Diabetes mellitus is a possible risk factor for the development of idiopathic pulmonary fibrosis (IPF), yet the effect of antidiabetic therapy on the course of IPF is unknown. - OBJECTIVES: This post hoc analysis assessed the effect of metformin on clinically relevant outcomes in patients with IPF. - METHODS: For the primary analysis, patients randomized to placebo (n = 624) in 3 phase 3, double-blind, controlled trials of pirfenidone (CAPACITY [NCT00287716 and NCT00287729]; ASCEND [NCT01366209]) were categorized by baseline metformin use. The primary outcome was disease progression (forced vital capacity [FVC] decline ≥10%, 6-min walking distance [6MWD] decline ≥50 m, or death). Other outcomes included mortality, hospitalization, FVC decline (≥10 and ≥5%), and 6MWD decline. Outcomes were also assessed in patients with diabetes and/or hyperglycemia (impaired glucose tolerance [IGT] and diabetes population [IGT-diabetes population]) and all patients included in the 3 studies (intention-to-treat [ITT] population). - RESULTS: Overall, 71 (11.4%) patients were metformin users and 553 (88.6%) were nonmetformin users. Baseline data were similar between groups, except for a higher percentage of males (84.5 vs. 73.2%) and a history of diabetes (98.6 vs. 11.6%) in metformin users versus nonmetformin users. The unadjusted 1-year analyses demonstrated no significant differences in disease progression or other outcomes. A higher proportion of metformin users compared with nonmetformin users had a relative FVC decline of ≥5% (63.4 vs. 50.6%, p = 0.043). Results were similar for the IGT-diabetes population and for the ITT population. Multivariable analyses yielded similar results. - CONCLUSIONS: Metformin has no effect on clinically relevant outcomes in patients with IPF..

Medienart:

E-Artikel

Erscheinungsjahr:

October 2018

2018

Erschienen:

October 2018

Enthalten in:

Zur Gesamtaufnahme - volume:96

Enthalten in:

Respiration - 96(2018), 4, Seite 314-322

Sprache:

Englisch

Beteiligte Personen:

Spagnolo, Paolo [VerfasserIn]
Kreuter, Michael, 1972- [VerfasserIn]
Maher, Toby M. [VerfasserIn]
Wuyts, Wim [VerfasserIn]
Bonella, Francesco [VerfasserIn]
Corte, Tamera J. [VerfasserIn]
Kopf, Stefan, 1978- [VerfasserIn]
Weycker, Derek [VerfasserIn]
Kirchgaessler, Klaus-Uwe [VerfasserIn]
Ryerson, Christopher J. [VerfasserIn]

Links:

Volltext [lizenzpflichtig]
Volltext [lizenzpflichtig]

Themen:

Aged
Anti-Inflammatory Agents, Non-Steroidal
Diabetes Mellitus
Diabetes mellitus
Disease Progression
Female
Humans
Hyperglycemia
Hypoglycemic Agents
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis
Male
Metformin
Middle Aged
Post hoc analysis
Pyridones
Vital Capacity

Anmerkungen:

Gesehen am 01.04.2020

Umfang:

9

doi:

10.1159/000489668

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

1693710153

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?